EP2801372A3 - Avoiding narcolepsy risk in influenza vaccines - Google Patents
Avoiding narcolepsy risk in influenza vaccines Download PDFInfo
- Publication number
- EP2801372A3 EP2801372A3 EP14167980.3A EP14167980A EP2801372A3 EP 2801372 A3 EP2801372 A3 EP 2801372A3 EP 14167980 A EP14167980 A EP 14167980A EP 2801372 A3 EP2801372 A3 EP 2801372A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- risk
- narcolepsy
- influenza vaccines
- avoiding
- vaccines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14167980.3A EP2801372A3 (en) | 2013-05-10 | 2014-05-12 | Avoiding narcolepsy risk in influenza vaccines |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361822228P | 2013-05-10 | 2013-05-10 | |
US201361859113P | 2013-07-26 | 2013-07-26 | |
US201361862807P | 2013-08-06 | 2013-08-06 | |
EP13181429 | 2013-08-23 | ||
EP14158999 | 2014-03-11 | ||
EP14167980.3A EP2801372A3 (en) | 2013-05-10 | 2014-05-12 | Avoiding narcolepsy risk in influenza vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2801372A2 EP2801372A2 (en) | 2014-11-12 |
EP2801372A3 true EP2801372A3 (en) | 2015-02-18 |
Family
ID=51660716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14167980.3A Withdrawn EP2801372A3 (en) | 2013-05-10 | 2014-05-12 | Avoiding narcolepsy risk in influenza vaccines |
Country Status (11)
Country | Link |
---|---|
US (3) | US20140335116A1 (ja) |
EP (1) | EP2801372A3 (ja) |
JP (1) | JP2016521282A (ja) |
KR (1) | KR20160030097A (ja) |
CN (1) | CN105828835A (ja) |
AU (1) | AU2014264501A1 (ja) |
BR (1) | BR112015028314A2 (ja) |
CA (1) | CA2911296A1 (ja) |
MX (1) | MX2015015428A (ja) |
SG (1) | SG11201509265SA (ja) |
WO (1) | WO2014180999A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2801372A3 (en) | 2013-05-10 | 2015-02-18 | Novartis AG | Avoiding narcolepsy risk in influenza vaccines |
EP3416981A1 (en) * | 2016-02-18 | 2018-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor |
US11428638B2 (en) | 2018-01-12 | 2022-08-30 | The Regents Of The University Of California | Spectroscopic biological material characterization |
CN111803625B (zh) * | 2020-09-09 | 2020-12-18 | 天津中逸安健生物科技有限公司 | 一种亚单位流感疫苗裂解剂及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006100110A1 (en) * | 2005-03-23 | 2006-09-28 | Glaxosmithkline Biologicals S.A. | Novel composition |
WO2007052061A2 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
PL355287A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
DE60142506D1 (de) | 2000-03-03 | 2010-08-19 | Chemo Sero Therapeut Res Inst | In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
PT1361890E (pt) | 2001-02-23 | 2011-06-07 | Glaxosmithkline Biolog Sa | Formulações vacinais de influenza para distribuição intradérmica |
EP1361889A1 (en) | 2001-02-23 | 2003-11-19 | GlaxoSmithKline Biologicals S.A. | Novel vaccine |
MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
EP1551228B1 (en) | 2002-06-13 | 2012-10-03 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
KR20070008625A (ko) | 2004-04-05 | 2007-01-17 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
CN101094915A (zh) | 2004-05-20 | 2007-12-26 | 益得生物医学公司 | 生产流感疫苗的方法 |
EP1831353B1 (en) | 2004-12-23 | 2012-02-29 | MedImmune, LLC | Non-tumorigenic mdck cell line for propagating viruses |
GB0506001D0 (en) * | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Novel use |
FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
NZ567817A (en) | 2005-11-01 | 2012-01-12 | Novartis Vaccines & Diagnostic | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
US8338593B2 (en) | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
CN101522218B (zh) | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
WO2008047174A1 (en) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
NZ577405A (en) | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
US8466167B2 (en) | 2008-03-03 | 2013-06-18 | Irm Llc | Compounds and compositions as TLR activity modulators |
PL2276486T3 (pl) | 2008-03-24 | 2014-04-30 | 4Sc Discovery Gmbh | Nowe podstawione imidazochinoliny |
DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
US9884105B2 (en) * | 2008-12-16 | 2018-02-06 | Ology Bioservices, Inc. | Production of viral vaccine |
CA2763440A1 (en) * | 2009-05-29 | 2010-12-02 | Novartis Ag | Assays for influenza virus hemagglutinins |
TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為tlr活性調節劑之化合物及組合物 |
GB0918830D0 (en) | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
EP2549990A1 (en) | 2010-03-23 | 2013-01-30 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
CN103313725B (zh) | 2010-09-01 | 2016-06-29 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
EP2801372A3 (en) | 2013-05-10 | 2015-02-18 | Novartis AG | Avoiding narcolepsy risk in influenza vaccines |
-
2014
- 2014-05-12 EP EP14167980.3A patent/EP2801372A3/en not_active Withdrawn
- 2014-05-12 AU AU2014264501A patent/AU2014264501A1/en not_active Abandoned
- 2014-05-12 BR BR112015028314A patent/BR112015028314A2/pt not_active Application Discontinuation
- 2014-05-12 CN CN201480039584.1A patent/CN105828835A/zh active Pending
- 2014-05-12 JP JP2016512393A patent/JP2016521282A/ja active Pending
- 2014-05-12 KR KR1020157034963A patent/KR20160030097A/ko not_active Application Discontinuation
- 2014-05-12 US US14/275,373 patent/US20140335116A1/en not_active Abandoned
- 2014-05-12 MX MX2015015428A patent/MX2015015428A/es unknown
- 2014-05-12 WO PCT/EP2014/059672 patent/WO2014180999A1/en active Application Filing
- 2014-05-12 SG SG11201509265SA patent/SG11201509265SA/en unknown
- 2014-05-12 CA CA2911296A patent/CA2911296A1/en not_active Abandoned
-
2016
- 2016-10-04 US US15/284,624 patent/US20170216425A1/en not_active Abandoned
-
2019
- 2019-03-06 US US16/293,867 patent/US20190184007A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006100110A1 (en) * | 2005-03-23 | 2006-09-28 | Glaxosmithkline Biologicals S.A. | Novel composition |
WO2007052061A2 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
Non-Patent Citations (7)
Title |
---|
ANNA KÄLL: "The Pandemrix - narcolepsy tragedy: how it started and what we know today", ACTA PAEDIATRICA, vol. 102, no. 1, 28 January 2013 (2013-01-28), pages 2 - 4, XP055089599, ISSN: 0803-5253, DOI: 10.1111/apa.12012 * |
ETTINGER RUTH A ET AL: "Allelic variation in key peptide-binding pockets discriminates between closely related diabetes-protective and diadetes-susceptible HLA-DQB1*06 alleles", JOURNAL OF IMMUNOLOGY, vol. 176, no. 3, February 2006 (2006-02-01), pages 1988 - 1998, XP002717114, ISSN: 0022-1767 * |
FANG HAN ET AL: "Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china", ANNALS OF NEUROLOGY, vol. 70, no. 3, 22 September 2011 (2011-09-22), pages 410 - 417, XP055089608, ISSN: 0364-5134, DOI: 10.1002/ana.22587 * |
JOSH MAHLIOS ET AL: "The autoimmune basis of narcolepsy", CURRENT OPINION IN NEUROBIOLOGY, vol. 23, no. 5, 29 May 2013 (2013-05-29), pages 767 - 773, XP055089594, ISSN: 0959-4388, DOI: 10.1016/j.conb.2013.04.013 * |
KRAHN LOIS E ET AL: "Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: Relationship to cataplexy and HLA DQB1*0602 status", SLEEP, ALLEN PRESS, LAWRENCE, KS, US, vol. 25, no. 7, 1 November 2002 (2002-11-01), pages 733 - 736, XP009174487, ISSN: 0161-8105 * |
RENFREY S ET AL: "Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom", VACCINE, ELSEVIER LTD, GB, vol. 12, no. 8, 1 January 1994 (1994-01-01), pages 747 - 752, XP023712145, ISSN: 0264-410X, [retrieved on 19940101], DOI: 10.1016/0264-410X(94)90227-5 * |
THEBAULT SIMON ET AL: "Narcolepsy and H1N1 vaccination: a link?", CURRENT OPINION IN PULMONARY MEDICINE NOV 2013, vol. 19, no. 6, November 2013 (2013-11-01), pages 587 - 593, XP002717112, ISSN: 1531-6971 * |
Also Published As
Publication number | Publication date |
---|---|
EP2801372A2 (en) | 2014-11-12 |
BR112015028314A2 (pt) | 2017-09-19 |
AU2014264501A1 (en) | 2015-12-10 |
US20170216425A1 (en) | 2017-08-03 |
SG11201509265SA (en) | 2015-12-30 |
MX2015015428A (es) | 2016-07-18 |
KR20160030097A (ko) | 2016-03-16 |
US20140335116A1 (en) | 2014-11-13 |
CA2911296A1 (en) | 2014-11-13 |
US20190184007A1 (en) | 2019-06-20 |
JP2016521282A (ja) | 2016-07-21 |
WO2014180999A1 (en) | 2014-11-13 |
CN105828835A (zh) | 2016-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261204A (en) | Influenza virus vaccines and their use | |
HK1214962A1 (zh) | 流感病毒免疫原性組合物及其應用 | |
ZA201700165B (en) | Influenza virus vaccines and uses thereof | |
HK1223110A1 (zh) | 流行性感冒病毒疫苗及其用途 | |
HK1216723A1 (zh) | 流感核酸分子和由其製備的疫苗 | |
SG11201610443WA (en) | Influenza virus vaccines and uses thereof | |
IL240936B (en) | Reassortment of influenza virus and methods for their preparation | |
ZA201608487B (en) | Dual adjuvant vaccine compositions, preparation and uses | |
IL251120B (en) | Immunogenic/therapeutic glycoside preparations and their uses | |
IL244354A0 (en) | Flu vaccine and treatment | |
HK1220656A1 (zh) | 減弱的流感病毒和疫苗 | |
HK1213800A1 (zh) | 類毒素、組合物及相關方法 | |
EP3022298A4 (en) | WAXED INFLUENZA VACCINE AND USES THEREOF | |
EP3013852A4 (en) | Methods and compositions for dengue virus vaccines | |
EP2801372A3 (en) | Avoiding narcolepsy risk in influenza vaccines | |
EP3302544A4 (en) | NANOPARTICLE-BASED VACCINE STRATEGY AGAINST SWINE INFLUENZA VIRUS | |
CL2015001618A1 (es) | Adyuvante de vacunación, preparación y vacunas que lo contienen | |
IL247531A0 (en) | The history of ksuz, their preparation and uses | |
HK1213917A1 (zh) | 類霉素、組合物及相關方法 | |
HK1201283A1 (en) | Influenza c virus and vaccine | |
EP3043815A4 (en) | Malaria vaccine | |
EP3239169A4 (en) | Conotoxin peptide -cptx-btl05, preparation method therefor, and uses thereof | |
HK1249066A1 (zh) | Isg15和其作為佐劑的用途 | |
IL249705B (en) | Influenza virus vaccines and their uses | |
IL249704A0 (en) | Influenza virus vaccines and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140512 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/005 20060101ALI20150112BHEP Ipc: A61K 39/145 20060101AFI20150112BHEP |
|
R17P | Request for examination filed (corrected) |
Effective date: 20150818 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
17Q | First examination report despatched |
Effective date: 20170207 |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: STEINMAN, LAWRENCE Owner name: VOLKMUTH, WAYNE Owner name: SEQIRUS UK LIMITED |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20190830 |